NCT06007690Phase 3Active not recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Study sponsor: Aura Biosciences

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-11-15Estimated
Enrollment · participants108Actual
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 108 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Primary completion date changed

Before: 1 Mar 2026. After: 15 Nov 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview